siRNA-mediated down-regulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53

Leukemia Research

Volumn 33, Issue 9, 2009, Pages 1243-1248

  Liu, Hang ^a   Wang, Min ^a   Diao, Shiyong ^a   Rao, Qing ^a   Zhang, Xinwei ^a   Xing, Haiyan ^a   Wang, Jianxiang ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Apoptosis; ASPP; iASPP; Leukemia; p53

Indexed keywords

DAUNORUBICIN; ETOPOSIDE; INHIBITOR OF ANKYRIN REPEAT SH3 DOMAIN AND PROLINE RICH REGION CONTAINING PROTEIN; INHIBITOR PROTEIN; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CELL DIVISION; CELL LINE, TUMOR; DAUNORUBICIN; DNA PRIMERS; DOWN-REGULATION; ETOPOSIDE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67649264588     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.02.016     Document Type: Article

References (14)

1. Hainaut P., Hernandez T., Robinson A., Rodriguez-Tome P., Flores T., Hollstein M., et al. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res 26 (1998) 205-213
2. http://www.p53.curie.fr/
3. Trigiante G., and Lu X. ASPPs and cancer. Nat Rev Cancer 6 (2006) 217-226
4. Slee E.A., and Lu X. The ASPP family: deciding between life and death after DNA damage. Toxicol Lett 139 (2003) 81-87
5. Yang J.P., Hori M., Sanda T., and Okamoto T. Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor. J Biol Chem 274 (1999) 15662-15670
6. Bergamaschi D., Samuels Y., O'Neil N.J., Trigiante G., Grook T., and Hsieh J.K. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 33 (2003) 162-167
7. Slee E.A., Gillotin S., Bergamaschi D., Royer C., Llanos S., and Ali S. The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization. Oncogene 23 (2004) 1-10
8. Zhang X., Wang M., Zhou C., Chen S., and Wang J. The expression of iASPP in acute leukemias. Leuk Res 29 (2005) 179-183
9. Elbashir S.M., Harborth J., Weber K., and Tuschl T. Analysis of gene function in somatic mammalian cells using a small interference RNAs. Methods 26 (2002) 199-213
10. Zhang X., Diao S., Rao Q., Xing H., Liu H., and Liao X. Identification of a novel isoform of iASPP and its interaction with p53. J Mol Biol 368 (2007) 1162-1171
11. Samuels-Lev Y., O'Connor D.J., Bergamaschi D., Triqiante G., Hsieh J.K., and Zhong S. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 8 (2001) 781-794
12. Gorina S., and Pavletich N.P. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274 (1996) 1001-1005
13. Tidow H., Veprintsev D.B., Freund S.M.V., and Fersht A.R. Effects of oncogenic mutations and DNA response elements on the binding of p53 to p53 binding protein 2 (53BP2). J Biol Chem 281 (2006) 32526-32533
14. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310